Extended Data Table 1.
Group differences calculated as differences of the means are displayed as differences between the groups, which describes the ability to separate the compared groups. Accuracy ranges for the differences of the means ≥80% as well as an effect size ≥80% were considered significant (*), differences of the means ≥ 90% as well as an effect size ≥ 90% were considered highly significant (**) (Johnson 2013).
| Bayesian posterior analysis | ||||
|---|---|---|---|---|
| group comparison | accuracy ranges of the differences of the means | significance | ||
| Fig. 1B | total LPA levels plasma | wt control vs. wt fasted | 96,9% | highly significant |
|
| ||||
| Fig. 1C | LPA subtypes plasma levels | wt control vs. wt fasted | ||
| LPA 16:0 plasma | 97,1% | highly significant | ||
| LPA 18:0 plasma | 89,9% | significant | ||
| LPA 18:2 plasma | 60,9% | n.s. | ||
| LPA 20:0 plasma | 99,7% | highly significant | ||
| LPA 20:4 plasma | 99,1% | highly significant | ||
|
| ||||
| Fig. 1D | LPA 18:1 plasma | wt control vs. wt fasted | 83,8% | significant |
|
| ||||
| Fig. 1E | LPA 18:1 CSF | wt control vs. wt fasted | 96,4% | highly significant |
|
| ||||
| Fig. 1F | LPA subtypes CSF levels | wt control vs. wt fasted | ||
| LPA 16:0 CSF | 98,7% | highly significant | ||
| LPA 18:0 CSF | 90,3% | highly significant | ||
| LPA 18:2 CSF | 76,9% | n.s. | ||
| LPA 20:0 CSF | 60,0% | n.s. | ||
| LPA 20:4 CSF | 89,2% | significant | ||
|
| ||||
| Fig. 4B | total LPA levels plasma | fasted control vs fasted AgRPDTR | 81% | significant |
|
| ||||
| Fig. 4C | LPA 18:1 plasma | fasted control vs fasted AgRPDTR | 90,5% | highly significant |
|
| ||||
| Fig. 4D | total LPA levels CSF | fasted control vs fasted AgRPDTR | 92,6% | highly significant |
| LPA 18:1 CSF | 68,4% | n.s. | ||
|
| ||||
| Fig. 4E | ratio LPA 18:1 / total LPA | fasted control vs fasted AgRPDTR | 93,5% | highly significant |
|
| ||||
| Suppl Fig. S4B | LPA subtypes CSF levels | wt control vs. wt + PF8380 | ||
| LPA 16:0 | 97,6% | highly significant | ||
| LPA 18:1 | 99,2% | highly significant | ||
| LPA 18:2 | 84,5% | significant | ||
| LPA 20:4 | 69,9% | n.s. | ||
|
| ||||
| Suppl. Fig. S5B | Food intake | Wt control vs. PRG-1R346T/+ | 86,7% | significant |
|
| ||||
| Suppl Fig. S6A | total LPC LPC 18:1 |
fasted control vs fasted AgRPDTR | 88,0% 86,8% |
significant significant |
|
| ||||
| Suppl Fig. S6B | LPA subtypes plasma levels | fasted control vs fasted AgRPDTR | ||
| LPA 16:0 plasma | 79,7% | n.s. | ||
| LPA 18:0 plasma | 84,4% | significant | ||
| LPA 18:2 plasma | 68,4% | n.s. | ||
| LPA18:3 plasma | 85,7% | significant | ||
| LPA 20:4 plasma | 55,1% | n.s. | ||
|
| ||||
| Suppl Fig. S6C | LPA subtypes CSF levels | fasted control vs fasted AgRPDTR | ||
| LPA 16:0 plasma | 68,8% | n.s. | ||
| LPA 18:0 plasma | 69,4% | n.s. | ||
| LPA 18:2 plasma | 97,3% | highly significant | ||
| LPA 20:4 plasma | 95,5% | highly significant | ||
|
| ||||
| Suppl Fig. S6E | ratio LPA subtypes / total LPA | fasted control vs fasted AgRPDTR | ||
| LPA 16:0 plasma | 90,2% | highly significant | ||
| LPA 18:0 plasma | 97,5% | highly significant | ||
| LPA 18:1 plasma | 93,5% | highly significant | ||
| LPA 18:2 plasma | 98,8% | highly significant | ||
| LPA 20:4 plasma | 70,5% | n.s. | ||